ReviewJournal of cardiovascular translational research2023

Empagliflozin for Patients with Heart Failure and Type 2 Diabetes Mellitus: Clinical Evidence in Comparison with Other Sodium-Glucose Co-transporter-2 Inhibitors and Potential Mechanism.

Bo Liang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.